Previous close | 0.7600 |
Open | 0.7500 |
Bid | 0.7722 x 200 |
Ask | 0.8299 x 200 |
Day's range | 0.7500 - 0.8200 |
52-week range | 0.5200 - 1.5700 |
Volume | |
Avg. volume | 426,865 |
Market cap | 39.262M |
Beta (5Y monthly) | 2.90 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
IceCure Medical (ICCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Key Insights IceCure Medical to hold its Annual General Meeting on 20th of May CEO Eyal Shamir's total compensation...
IceCure Medical (ICCM) submits final ICE data along with multiple sub-analysis to the FDA seeking approval for marketing authorization for treating early-stage breast cancer.